Mass General Brigham Cancer Institute
Tracked across 3 events · 130 articles · First seen Aug 11, 2026 · Last active Aug 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
A large U.S. study published in the journal Gastro Hep Advances found that daily consumption of sugar-sweetened beverages is associated with a more than doubled risk of stomach (gastric) cancer. Researchers from the Mass General…
Impact: Conducted and published the study, enhancing its reputation in cancer research.
Aug 17, 2026 · 20 articles
Business
Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on rare vascular diseases, announced the closing of an oversubscribed $152 million Series B financing and the initiation of its global Phase 3 HEROIC study. The financing was…
Impact: Affiliation of the Principal Investigator, supporting the trial's clinical oversight.
Aug 11, 2026 · 8 articles
Tech
Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for…
Impact: Mass General Brigham's experts commented on the trial, reflecting clinical relevance.
Aug 19, 2026 · 102 articles
ERGEN INTELLIGENCE
Track Mass General Brigham Cancer Institute live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard